As volatility creeps into Dynavax Technologies Corporation (NASDAQ:DVAX), investors need to pay close attention to to the factors affecting stock today as its shares are trading 4.73% or 0.235 points down from last closing price of $4.97, reaching $4.735 at last check. The DVAX share price has dropped in 5 of the last 5 days and is down -45.98% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -1,315,876 shares, and in total 305724 shares valued at $1.448 million were seen changing hands compared with 1.622 million shares valued at $8.059 million recorded at the previous session. You should take into consideration that a falling volume on lower prices shows the bearish trend but this is an early indication which means that the DVAX stock is near its bottom.
Dynavax Technologies Corporation (DVAX) shares have notched a 3-month decline of about -45.98%, but has still tumbled -45.68% year to date. By comparison, the stock sank -68.94% over the past 12 months, while it slipped -25.26% over the 1 month. The company’s market cap is around $355.31M, with its short interest ratio standing at 13.57%.
In the current trading session for DVAX, the stock witnessed two major price actions, it rose to a high of $4.89 and was down as much as $4.69 at one point. The high recorded is very low when compared to their 52-week high which is $4.9. The 52-week high is now at -71.97 distance from current price. Their recent low of $16.88 represents a -3.47% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for DVAX is $29.75, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
The stock of Dynavax Technologies Corporation earned $-2.54 per share in the trailing 12 months and has a P/E ratio of -1.86. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 69.3 and lower compared to the sector’s average of 32.55. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. DVAX also has P/S multiple of 24.53. This is smaller versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 49.5x.
The company recorded an interesting insider sale transaction by the VP on Feb 28, 2019. A Securities and Exchanges Commission filings show that David Louis Johnson sold a total of 20,765 DVAX shares that day for a sum of around $187,508. The filings show that the insider now retains 52,786 shares, currently worth $249,942. Dynavax Technologies Corporation (DVAX) insiders have acquired no shares in the stock within the past three months. The total insider sales reported to the SEC in that time frame amounted to shares. In total, individual insiders traded no shares in the business, which makes up 0% of 353,005 shares that were traded over a year. In the past 12 months, insiders have purchased zero shares while the seller parted with 353,005 shares.
DVAX‘s last price was down -52.83% as compared to the average trading price of 50 days recorded at $10.04 while enlarging the period to 200 trading days, the average closing price was $6.77. At present, there are 71.49 million in the total number of common shares owned by the public and among those 64.3 million shares have been available to trade. The percentage of shares being held by the company management was 1% while institutions stake was 82.5%. The company has generated negative returns on equity over the last 12 months (-190.8%). It managed to keep its gross profit margin at 36.9% over the past 12 months.
When assessing the full upside of the DVAX stock, there is another set of technicals that should be looked into and considered. Its -26.95% decline from moving average of $6.48 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 0.66 to the stock. With the beta been less than one, this implies that the company shares are theoretically less volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of Dynavax Technologies Corporation — 4 analysts rate the stock as a buy with another 0 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $23.6667 on shares of Dynavax Technologies Corporation (NASDAQ:DVAX), which corresponds to 401.41% upside potential than its current market price of $4.735 and implies potential despite the recent drop in the price. However, their current target price has fallen from $27 a month ago and is down handily from the consensus target of $27 a quarter ago.
In the last five years, the EPS of the company has been roughly 7.8%. Though the percentage looks disappointing, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has retreated at an average annualized rate of about -6.1 over the last five years. The company recently recorded an increase of 3398.8%, but this figure is rather attractive.
Let’s briefly check the hedge fund interest towards DVAX stock. Marshall Wace North America L.P. added position in the company after it grew 50% or 133,939 shares of its common stock. The hedge fund now owns 200,909 shares worth $951,304, SEC documents show. Marshall Wace LLP shored up assets in the stock as 11674.24 shares have been purchased, increasing its stake by 40.9% to 16,449 shares which are currently valued at $77,886. In addition, Clearbridge Investments LLC recently reported that it now owns 1,161,338 shares making a total of $5,498,935 based on the recent price. This refelects a change of 3.2% in their ownership.